Linzagolix will only be available for patients whose previous medical or surgical treatments have been unsuccessful.

A new daily tablet for endometriosis, called linzagolix (also known as Yselty), has been approved for use on the NHS and is ...

A new at-home pill for endometriosis has been approved for use on the NHS.The once-a-day tablet, called linzagolix but also ...

Clinical trials have shown linzagolix significantly reduces both menstrual pain and non-menstrual pelvic discomfort compared ...

Pfizer and Myovant have begun a late-stage trial of their potential uterine fibroid drug relugolix, as part of a contraceptive combination tablet. The FDA is already reviewing data from two ...

Myovant has chalked up a second approval for its flagship drug relugolix from the FDA, becoming the first once-daily oral drug in the US to treat heavy menstrual bleeding associated with uterine ...

Linzagolix (Yselty) with hormonal add-back therapy will offer a new at-home treatment option for some women in England with ...

The pill, known as relugolix–estradiol–norethisterone (or relugolix combination therapy, branded as Ryeqo), is considered a breakthrough for the 1.5 million people in the UK living with ...

Relugolix–estradiol–norethisterone (relugolix combination therapy [CT]) can be used, within its marketing authorisation, as an option for treating symptoms of endometriosis in adults of reproductive ...

In March 2025, the National Institute for Health and Care Excellence (NICE) approved a new daily pill, relugolix-estradiol-norethisterone (Ryeqo), for use in the NHS in England. This medication ...